AnodyneWiki

Dihydroergotamine

DHE
Dihydroergotamine
Salts
[]
Dihydroergotamine mesylate
Dihydroergotamine mesylate
Dihydroergotamine hemitartrate
Dihydroergotamine hemitartrate
Molecular structure drawn from PubChem coordinates
Physical properties
[]
Molecular mass583.70 g/mol [1]
Solubility2.29e-01 g/L [1]
Predicted LogP2.4 [1]
Structural Identifiers
[]
Molecular formulaC33H37N5O5
IUPAC name(6aR,9R,10aR)-N-[(1S,2S,4R,7S)-7-benzyl-2-hydroxy-4-methyl-5,8-dioxo-3-oxa-6,9-diazatricyclo[7.3.0.02,6]dodecan-4-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
SMILESC[C@@]1(C(=O)N2[C@H](C(=O)N3CCC[C@H]3[C@@]2(O1)O)CC4=CC=CC=C4)NC(=O)[C@@H]5C[C@H]6[C@@H](CC7=CNC8=CC=CC6=C78)N(C5)C
InChIInChI=1S/C33H37N5O5/c1-32(35-29(39)21-15-23-22-10-6-11-24-28(22)20(17-34-24)16-25(23)36(2)18-21)31(41)38-26(14-19-8-4-3-5-9-19)30(40)37-13-7-12-27(37)33(38,42)43-32/h3-6,8-11,17,21,23,25-27,34,42H,7,12-16,18H2,1-2H3,(H,35,39)/t21-,23-,25-,26+,27+,32-,33+/m1/s1
InChIKeyLUZRJRNZXALNLM-JGRZULCMSA-N
CAS number511-12-6
UNII436O5HM03C
PubChem CID10531
Pharmacokinetics[]
Elimination half-life9 hours
ExcretionBile duct
Routes of administrationNasal, subcutaneous, intramuscular, intravenous

Dihydroergotamine (also known as 9,10-Dihydroergotamine, Dihidroergotamina, Dihydroergotaminum, Neomigran, Diidroergotamina, Agit, Map0004, Map-0004, 5'-Benzyl-12'-hydroxy-2'-methyl-3',6',18-trioxo-9,10-dihydroergotaman or 9,10-Dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)ergotoman-3',6',18-trione) is a substance of the ergoline and lysergamide class.

Chemistry

Salts []

Dihydroergotamine is typically found in the form of its mesylate and hemitartrate salts.

 []

Dihydroergotamine is a single defined stereoisomer.

Dihydroergotamine matches Lipinski's rule of five (violations: 1).

Pharmacology

Mechanism of action []

DHE has several proposed mechanisms which may contribute to its therapeutic efficacy as an abortive therapy in migraines. Firstly, DHE's s agonist action on 5-hydroxytryptamine (5HT) 1b receptors in the smooth muscle of the cranial vasculature may provide relief via vasoconstriction of the blood vessels which typically become dilated due to the release of CGRP during migraine attacks. DHE's off-target action at alpha-adrenergic receptors may further contribute via this mechanism. The remaining mechanisms are thought to provide relief through the effects on the neurogenic causes of migraine symptoms. Agonist action by DHE on 5-HT<sub>1b</sub> and 5-HT<sub>1d</sub> receptors inhibits nociceptive signalling through the ventroposteromedial thalamus to the trigeminal sensory neurons. Further action on 5-HT<sub>1b</sub> and 5-HT<sub>1d</sub> receptors with the addition of agonist activity on 5-HT<sub>1f</sub> in the trigeminal nucleus caudalis decreases afferent signalling to trigeminal sensory neurons which contributes to central sensitization. The success of experimental compounds selectively targetting the 5-HT<sub>1f</sub> receptor lends support to this mechanism. Lastly, action at 5-HT<sub>1d</sub> receptors on trigeminal nerve terminals inhibits the release of vasoactive neuropeptides thought to contribute to pain and inflammation during a migraine attack. DHE is known to have 10-fold less potency at the 5-HT<sub>1b</sub> receptor than its predecessor ergotamine which reduces the incidence of vascular side effects. Notably, DHE slowly diffuses from receptors resulting in unreliable prediction of effects from plasma concentration. [1]

Interactions []

Interaction mechanisms documented in (number of interacting drugs):

metabolism / induction / inhibition81 (11 contraindicated)
shared target7 (6 contraindicated)
shared target7 (6 contraindicated)

Medical side effects []

115 side effects listed on drug labels in (dihydroergotamine).

  • Rhinitis
  • Nausea
  • Application site reaction
  • Vomiting
  • Pharyngitis
  • Somnolence
  • Asthenia
  • Fatigue
  • Sinusitis
  • Dry mouth
  • Musculoskeletal stiffness
  • Menopausal symptoms
  • Hot flush
  • Abdominal pain
  • Gastrointestinal pain
  • Confusional state
  • Feeling abnormal
  • Malaise
  • Conjunctivitis
  • Cystitis
  • Bladder pain
  • Cystitis noninfective
  • Dysphagia
  • Dyspepsia
  • Ear pain
  • Oedema
  • Body temperature increased
  • Hiccups
  • Hypoaesthesia
  • Muscle spasms
  • Nervousness
  • Tension
  • Palpitations
  • Petechiae
  • Pruritus
  • Tachycardia
  • Tinnitus
  • Tremor
  • Upper respiratory tract infection
  • Pollakiuria
  • Vertigo
  • Photophobia
  • Periorbital oedema
  • Muscular weakness
  • Discomfort
  • Ill-defined disorder
  • Myalgia
  • Musculoskeletal discomfort
  • Arthralgia
  • Euphoric mood
  • Disturbance in attention
  • Mental disability
  • Cold sweat
  • Lacrimal disorder
  • Chills
  • Insomnia
  • Parosmia
  • Visual impairment
  • Angina pectoris
  • Decreased appetite
  • Anxiety
  • Aphonia
  • Bronchospasm
  • Bronchitis
  • Pleuritic pain
  • Diarrhoea
  • Dizziness
  • Dyspnoea
  • Epistaxis
  • Oesophageal spasm
  • Dermatitis
  • Rash
  • Flushing
  • Headache
  • Herpes simplex
  • Hypertension
  • Hypotension
  • Muscle rigidity
  • Myocardial infarction
  • Acute coronary syndrome
  • Paraesthesia
  • Tingling sensation
  • Retroperitoneal fibrosis
  • Shock
  • Salivary hypersecretion
  • Speech disorder
  • Cerebrovascular accident
  • Urticaria
  • Vaginal inflammation
  • Vaginal infection
  • Yawning
  • Vasospasm
  • Stupor
  • Depressed level of consciousness
  • Migraine
  • Migraine aggravated
  • Eye pain
  • Muscle contractions involuntary
  • Peripheral ischaemia
  • Pelvic inflammatory disease
  • Influenza like illness
  • Agitation
  • Hyperkinesia
  • Gait disturbance
  • Hyperhidrosis
  • Rash papular
  • Arteriospasm coronary
  • Hypersensitivity
  • Pain
  • Swelling
  • Ventricular fibrillation
  • Ventricular tachycardia
  • Injury
  • Myocardial ischaemia
  • Face oedema

Indications

  • Acute myocardial infarction
  • Angina pectoris
  • Arteriospasm coronary
  • Aura
  • Basilar migraine
  • Blood pressure increased
  • Cardiovascular disorder
  • Cerebral haemorrhage
  • Cerebral ischaemia
  • Cerebrovascular accident
  • Cluster headache
  • Coldness
  • Colitis ischaemic
  • Coronary artery disease
  • Cyanosis
  • Fibrosis
  • Gangrene
  • Hepatic impairment
  • Hypersensitivity
  • Hypertension
  • Ischaemia
  • Microsomia
  • Migraine
  • Myalgia
  • Myocardial infarction
  • Myocardial ischaemia
  • Numbness
  • Pallor
  • Peripheral arterial disease
  • Prinzmetal angina
  • Retroperitoneal fibrosis
  • Sepsis
  • Subarachnoid haemorrhage
  • Uncontrolled hypertension
  • Vasospasm

 []

  • Brazil: Dihydroergotamine is a D1.[3]
  • United States: Dihydroergotamine is Prescription only.[4][5][6][7]

See also []

External links []

References []

  1. National Center for Biotechnology Information. PubChem Compound Summary for CID 10531, Dihydroergotamine. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/10531
  2. U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Dihydroergotamine. UNII: 436O5HM03C. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/436O5HM03C
  3. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 31 March 2023. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
  4. D.H.E. 45- dihydroergotamine mesylate injection, solution. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fe826e6a-75c8-43ed-9c36-f8263ec35aff
  5. Migranal- dihydroergotamine mesylate spray. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a24befa8-b952-48ac-942a-379585250782
  6. Dromelate- dihydroergotamine mesylate injection, solution. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2367e853-1109-4c23-a177-6829304832e8
  7. Trudhesa- dihydroergotamine mesylate spray, metered. DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b81397b0-910d-4eb4-8fee-a9a3c9d94d63

Data sources []

SourceStatusUpdated (UTC)
dosingmissing (no dosing statistics)2026-11-20 03:05:32
drugspromissing (no DrugsPRO reagent data)2026-11-20 03:05:28
erowidmissing (no Erowid substance of that name)2026-11-20 03:05:28
gsrsok2026-11-20 03:05:29
hmdbmissing (hmdb.ca refused automated access to HMDB0014465)2026-11-20 03:05:28
keggok2026-11-20 03:05:30
pubchemok2026-11-20 03:05:27
redditmissing (no r/tripreports posts mention it)2026-11-20 03:05:28
siderok2026-11-20 03:05:28
structureok2026-11-20 03:05:28
wikipediaok2026-11-20 03:05:28